New chelation therapies and emerging chelating drugs for the treatment of iron overload

Expert Opinion on Emerging Drugs
George J Kontoghiorghes

Abstract

Iron chelation therapy using deferoxamine or deferiprone (L1) is effective for the treatment of most transfused iron-loaded patients. The combination administration of deferiprone in the daytime and deferoxamine in the night appears to be universally effective in rapidly achieving negative iron balance. The cardiac iron removal effect of deferiprone increases the prospects of longer survival in beta-thalassaemia patients. New chelators have reached the stage of clinical development such as deferitrin, 1-allyl-2-methyl-3-hydroxypyrid-4-one (L1NAll) and the starch deferoxamine polymers. Deferasirox has received a conditional approval in the US under the FDA-accelerated approval regulations, but needs further verification of its efficacy and safety. Future iron chelation therapies are likely to be based on combinations of chelating drugs.

References

Jan 19, 2000·The Journal of Laboratory and Clinical Medicine·P R DragstenB E Hedlund
May 16, 2000·Ultrastructural Pathology·K KyriacouC Zambartas
Jun 27, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·George J KontoghiorghesAnnita Kolnagou
Oct 7, 1964·Annals of the New York Academy of Sciences·H KEBERLE
Mar 2, 2005·Best Practice & Research. Clinical Haematology·M D Cappellini

❮ Previous
Next ❯

Citations

Sep 28, 2007·European Journal of Pediatrics·Christiane Vermylen
Nov 9, 2007·Journal of Computer-aided Molecular Design·John H Van Drie
Nov 5, 2008·Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine·Premysl MladenkaRadomír Hrdina
Dec 20, 2015·Bioorganic & Medicinal Chemistry Letters·Vincent CorcéDavid Deniaud
May 20, 2008·Biochimica Et Biophysica Acta·D R RichardsonD B Lovejoy
Feb 4, 2014·Cancer Letters·Oriana MarquesCarlos Lopes
Oct 21, 2006·Current Opinion in Hematology·Claudia R MorrisMark C Walters
Jan 14, 2009·Cancer Prevention Research·Trevor M Penning, Caryn Lerman
Jun 8, 2021·Microbiological Research·Behnoush KhasheiiAbdolmajid Mohammadzadeh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

© 2021 Meta ULC. All rights reserved